Immunome is a clinical-stage biotechnology company focused on developing targeted therapies for cancer. The company's lead program, Varegacestat, is a gamma secretase inhibitor currently in Phase 3 clinical trials for desmoid tumors. Its clinical portfolio also includes IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate in Phase 1 development. The company maintains several preclinical-stage programs, including IM-3050, a fibroblast activation protein-targeted radioligand therapy, alongside a series of solid tumor antibody-drug conjugate candidates.
The company operates as a pre-revenue clinical-stage entity, with development activities concentrated on oncology indications. Immunome is headquartered in Bothell, Washington, and operates with a workforce of 168 full-time employees. The company was incorporated in Delaware in 2006 and is traded on the Nasdaq exchange.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-5.00 | $-5.00 | +7.1% | |
| 2023 | $-5.38 | $-5.38 | -74.1% | |
| 2022 | $-3.09 | $-3.09 | -44.4% | |
| 2021 | $-2.14 | $-2.14 | — | |
| 2020 | — | — | — |